Boston Scientific has disclosed that a recent cybersecurity incident will materially impact its Q3 and full-year 2026 financial results, leading to a downward revision of its net sales growth and adjusted EPS guidance. While the company is working to restore operations and expects to recover some revenue, the full financial implications are still unknown, creating near-term uncertainty for investors.
Boston Scientific (BSX) has revealed that a cybersecurity incident, previously disclosed on August 26, 2026, will materially impact its Q3 and full-year 2026 financial performance. This has led the company to state it is unlikely to meet its previously provided net sales growth and adjusted EPS guidance. The incident disrupted manufacturing, order processing, and shipping, though the company is making progress in restoring systems. This news is a significant negative catalyst for BSX in the short term, as it directly impacts profitability and revenue expectations. While the company does not expect a material long-term impact, the uncertainty surrounding the full recovery timeline and financial hit will likely weigh on the stock until more concrete figures are provided in October. Traders should anticipate downward pressure on BSX shares due to the reduced guidance and operational disruption.